Table 1.
Study | Phase | Aim | Enrolled patients | Status |
NCT00733876 | Phase 1 | To determine the safety of the administration of allogeneic MSCs at defined doses in patients with high risk of developing AKI after undergoing on-pump cardiac surgery | 15 | Completed[52] |
NCT01275612 | Phase 1 | To test the feasibility and safety of systemic infusion of donor ex-vivo expanded MSCs to repair kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin | 3 (estimated enrollment 9 patients) | Ongoing and recruiting patients |
NCT01602328 | Phase 2 | To evaluate kidney recovery after a single injection of allogeneic bone marrow derived MSCs in patients who experience kidney injury within 48 h of their cardiac surgery | 156 | Terminated |
MSCs: Mesenchymal stem cells; AKI: Acute kidney injury.